Biocon partner Mylan gets favorable ruling in patent case on Insulin Glargine
Updated : June 02, 2020 02:43 PM IST
Biocon and Mylan are currently awaiting the US drug regulator’s final nod for insulin glargine.
Biocon expects to launch the drug in the US markets by the middle of this calendar year.
The drug insulin glargine is a long-acting insulin used to manage both Type 1 and Type 2 diabetes.